Spectrum Pharma Signs A Strategic Partnership With Servier Canada

HENDERSON, Nev. & LAVAL, Quebec--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc. (NasdaqGS:SPPI), a biotechnology company with fully integrated commercial and drug development operations and a primary focus in Hematology and Oncology and Servier Canada Inc., an affiliate of Servier a research-oriented pharmaceutical company which is pioneering new therapies primarily for cancer and cardiovascular diseases, announce the signing of a strategic partnership. As part of this partnership, Spectrum will grant the exclusive rights to develop and commercialize in Canada a franchise of four Spectrum hemato-oncology drugs: ZEVALIN® (ibritumomab tiuxetan) Injection for intravenous use, Folotyn®(pralatrexate injection), Beleodaq® (belinostat) for Injection and Marqibo® (vinCRIStine sulfate LIPOSOME injection) for intravenous infusion. Spectrum will receive $6 million in upfront payments, plus development milestone payments and royalties based on net product sales.